期刊
IMMUNITY
卷 44, 期 2, 页码 343-354出版社
CELL PRESS
DOI: 10.1016/j.immuni.2015.11.024
关键词
-
类别
资金
- Samana Cay MGH Research Scholar Fund
- NIH [P50-CA86355, R01-AI084880, U54-CA126515, 5U54CA163125, 5U54-CA163109]
- Howard Hughes Medical Institute
- Deutsche Forschungsgemeinschaft (DFG) [PF809/1-1]
- Boehringer Ingelheim Fonds
- DFG [RI2408/1-1]
Checkpoint blockade immunotherapies can be extraordinarily effective, but might benefit only the minority of patients whose tumors are pre-infiltrated by T cells. Here, using lung adenocarcinoma mouse models, including genetic models, we show that autochthonous tumors that lacked T cell infiltration and resisted current treatment options could be successfully sensitized to host antitumor T cell immunity when appropriately selected immunogenic drugs (e.g., oxaliplatin combined with cyclophosphamide for treatment against tumors expressing oncogenic Kras and lacking Trp53) were used. The antitumor response was triggered by direct drug actions on tumor cells, relied on innate immune sensing through toll-like receptor 4 signaling, and ultimately depended on CD8(+) T cell antitumor immunity. Furthermore, instigating tumor infiltration by T cells sensitized tumors to checkpoint inhibition and controlled cancer durably. These findings indicate that the proportion of cancers responding to checkpoint therapy can be feasibly and substantially expanded by combining checkpoint blockade with immunogenic drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据